China Everbright Bank Shares Fall on Earnings Miss
By Amanda Lee
China Everbright Bank's shares fell sharply after annual profit came in well short of expectations, with the lender's bottomline hurt by weaker net interest income and a surge in fourth-quarter provisions.
Shares of the Chinese commercial lender were 11% lower at 2.30 Hong Kong dollars (US$0.29) at the midday break Thursday, taking the stock into the red for year. If the level holds, it will mark the bank's biggest one-day percentage decline since listing in Hong Kong in 2013.
China Everbright Bank said late Wednesday that 2023 net profit fell 9.0% to 40.79 billion yuan (US$5.64 billion), well short of a consensus estimate of CNY45.40 billion by a FactSet poll of analysts. Net interest income fell 5.4% to CNY107.48 billion, but also missed expectations, while net fee and commission income fell 11%.
In the fourth quarter, profit fell to CNY3.10 billion from CNY13.62 billion in the third quarter amid a surge in provisions under a new drive to tighten nonperforming loan standards.
Citi Research analysts flagged a lack of "meaningful" dividend payout percentage hike, and said asset quality outlook remains uncertain.
Still, they kept a buy rating on the stock with a target price of HK$3.02, citing resilient loan growth and "decent trading gains."
"We think the worst for CEB is over as capital constraints have eased, while stronger-than-peers' deposit growth has been a positive surprise," they wrote in a research note.
Write to Amanda Lee at amanda.lee@wsj.com
Corrections & Amplifications
This item was corrected at 0639 GMT because the company 2023 net interest income fell 5.4 percent, not rose.
(END) Dow Jones Newswires
March 28, 2024 01:22 ET (05:22 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth